Citi opened an “upside 90-day catalyst watch” on Olema Oncology (OLMA) while keeping a Buy rating on the shares with a $62 price target The company will present initial clinical results for OP-3136 at ASCO which could drive share upside, the analyst tells investors in a research note. Citi believes the results could suggest differentiation and possibly potential in indications beyond breast cancer.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Pharmaceuticals: Citi’s Anupam Rama Reiterates Buy on Underappreciated Palazestrant Upside and Long-Term Pipeline Catalysts
- Olema Oncology price target lowered to $35 from $38 at Guggenheim
- Olema Pharmaceuticals: Differentiated KAT6i and Palazestrant Pipeline Catalysts Underpin Buy Rating
- Olema Oncology reports Q1 EPS (52c), consensus (54c)
- Olema Pharmaceuticals Signs New Headquarters Lease at Oyster Point